Rituximab infection risk under the microscope
NCT ID NCT03778840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study followed 73 people with autoimmune diseases like rheumatoid arthritis or multiple sclerosis who were starting treatment with rituximab. The goal was to track how many developed serious infections and to understand what factors increase that risk. Researchers also looked at whether giving intravenous immunoglobulins could help prevent infections. The findings may help doctors use rituximab more safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab
What this could lead to
If successful, this could help doctors better predict and prevent serious infections in patients taking rituximab for autoimmune diseases.
What could go wrong
This is an observational study, not a treatment trial. It aims to gather data, not test a new therapy, so it won't directly change care yet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Claude Huriez, CHU
Lille, France